Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 17/20 | 1.00 |
| ▸ | CXCR1 | P25024 | 15/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846981 | 0.91 | CXCR1 (1.00) | CXCR2CXCR1 | |
| SCHEMBL5845430 | 0.90 | CXCR2 (0.81) | CXCR2CXCR1GABRA5 | |
| SCHEMBL5846179 | 0.90 | CXCR2 (0.81) | CXCR2CXCR1MEN1LMNAKMT2A | |
| SCHEMBL5845309 | 0.90 | CXCR2 (0.81) | CXCR2CXCR1MEN1LMNAKMT2A | |
| SCHEMBL2158636 | 0.89 | CXCR2 (0.80) | CXCR2CXCR1MEN1LMNAKMT2A | |
| SCHEMBL5845483 | 0.88 | CXCR2 (0.84) | CXCR2CXCR1GABRA5 | |
| SCHEMBL5846283 | 0.88 | CXCR2 (0.84) | CXCR2CXCR1GABRA5 | |
| SCHEMBL5846801 | 0.88 | CXCR2 (0.78) | CXCR2CXCR1GABRA5 | |
| SCHEMBL5660485 | 0.87 | CXCR2 (0.77) | CXCR2CXCR1MEN1LMNAKMT2A | |
| SCHEMBL5846575 | 0.86 | CXCR1 (0.76) | CXCR2CXCR1GABRA5P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151112-B1 | Pharmaceutical uses and synthesis of nicotinamides | UCB SA (GB) | 2006-12-19 | — | — | US | disclosed |
| US-6777432-B1 | TREATING A SUBJECT HAVING AN INFLAMMATORY DISORDER ALLEVIATED BY THE INHIBITION OF GRO- ALPHA CYTOKINES | DARWIN MOLECULAR CORPORATION | 2004-08-17 | — | — | US | disclosed |